Filter Results:
(83)
Show Results For
- All HBS Web
(187)
- People (1)
- News (51)
- Research (83)
- Events (3)
- Multimedia (8)
- Faculty Publications (52)
Show Results For
- All HBS Web
(187)
- People (1)
- News (51)
- Research (83)
- Events (3)
- Multimedia (8)
- Faculty Publications (52)
Sort by
- 23 Mar 2021
- Book
Succeeding in the New Work-from-Anywhere World
than fifty years, self-disclosure has been widely studied across a variety of interpersonal contexts, including friendships, romances, and therapeutic relations. The way to enhance trust between people is for all parties to self-disclose,... View Details
Keywords: by Michael Blanding
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
"But in order to determine that genetic information has a therapeutic use, we have to make a substantial investment—$350 to $500 million—in doing the clinical trial work. From a business standpoint, we need to protect our... View Details
- 14 May 2020
- Research & Ideas
What Leaders Can Do to Fight the COVID Fog
well (and no one is there to watch you). Exercise is also an area where individuals have a great deal of control, which makes it a therapeutic activity in times of uncertainty. Short-term bursts of strenuous activity are not only... View Details
Keywords: by Boris Groysberg and Robin Abrahams
- 20 Sep 2016
- First Look
September 20, 2016
since it was started, with no therapeutic product available in the foreseeable future, Kaplan is considering whether it is time to change the company's business model. Purchase this case:... View Details
Keywords: Sean Silverthorne
- 11 Apr 2017
- First Look
First Look at New Research, April 11
treated with unproductive therapies while more easily uncovering therapeutic signals. However, such research initiatives alone will not deliver new medicines to patients in the absence of strong incentives to bring new products to market.... View Details
- 18 Dec 2018
- First Look
New Research and Ideas, December 18, 2018
from other firms, rather than developing new projects internally. Examining the channels behind this increase in R&D in-licensing, we explore heterogeneity in treatment effects and competitor spillovers. We find that competitors move resources away from affected... View Details
Keywords: Dina Gerdeman
- 15 Jan 2019
- First Look
New Research and Ideas, January 15, 2019
forthcoming American Journal of Therapeutics Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses By: Weitzman, Rachel E., Ariel Dora Stern, and Daniel B. Kramer Abstract—No abstract... View Details
Keywords: Dina Gerdeman
- 25 Jul 2005
- Research & Ideas
An Organization Your Customers Understand
segmentation focuses on customer demographics: Will products be designed to appeal to wealthy, middle-market, or low-income customers? For the pharmaceutical business, segmentation is by therapeutic class: Will the firm focus on research... View Details
Keywords: by Robert Simons
- 31 Oct 2004
- Research & Ideas
Bypass Marketing: Are Docs Influenced?
heartburn, advertising may do more harm than good. Silk: Keep in mind that the use of DTCA by pharmaceutical companies is quite selective in that it tends to be concentrated in a relatively small number of therapeutic classes. The... View Details
Keywords: by Manda Salls
- 28 Apr 2009
- First Look
First Look: April 28, 2009
Industry Location and International Regulatory Variation Author:Arthur A. Daemmrich Publication:Chap. 16 in Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms. Vol. 363, 271-290. Berlin, Germany: Max Planck... View Details
Keywords: Martha Lagace
- 09 Aug 2016
- First Look
August 9, 2016
drugs that have been shown to be therapeutically equivalent to an already approved original biologic drug—have only been approved in the United States since 2015. Europe has had biosimilar entry since 2006. This paper considers how... View Details
Keywords: Sean Silverthorne
- 01 Sep 2015
- First Look
First Look -- September 1, 2015
(TDABC) is an innovative costing tool in healthcare that can be used to directly compare the true cost of competing technologies over the full care cycle. Rather than only comparing therapeutic effectiveness over a limited number of... View Details
Keywords: Sean Silverthorne
- 13 Jun 2005
- Research & Ideas
From Turf Wars to Learning Curves: How Hospitals Adopt New Technology
substitutable and the physician groups associated with each moved into closer competition with each other. Where turf wars do seem to have more of an impact is in how aggressively a hospital supports its initial investment in a given View Details
- 09 Feb 2016
- First Look
February 9, 2016
a proxy contest and a special shareholder meeting to vote on replacing Allergan's directors with a slate more favorable to the Valeant merger. The proposed Salix acquisition would give Allergan a new therapeutic market but would also make... View Details
Keywords: Sean Silverthorne
- 01 Aug 2017
- First Look
First Look at New Research and Ideas, August 1
drugs (chemically-synthesized, “small-molecule” drugs) face price competition from generic drugs after patent expiration, biosimilars—biologic drugs that have been shown to be therapeutically equivalent to an already approved original... View Details
Keywords: Sean Silverthorne
- 08 Jun 2010
- First Look
First Look: June 8
uncertainty of commercial partners' interest in the therapeutic approach, and the constrained donor-based fundraising environment. Purchase this case:http://cb.hbsp.harvard.edu/cb/product/610074-PDF-ENG Data.gov Karim R. Lakhani, Robert... View Details
Keywords: Martha Lagace
- 11 May 2010
- First Look
First Look: May 11
narrowing horizontal breadth from over a dozen therapeutic classes to just three. In 2005, Levin hired Deborah Dunsire from Novartis as CEO to lead Millennium's continuing transformation. Students are asked to put themselves in the shoes... View Details
Keywords: Martha Lagace
- 31 Oct 2017
- First Look
New Research and Ideas, October 31, 2017
Potential of Patient-Reported Outcomes By: Rotenstein, Lisa, Robert S. Huckman, and Neil Wagle Abstract—No abstract available. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53372 forthcoming Clinical Pharmacology & View Details
Keywords: by Sean Silverthorne
- 18 Apr 2019
- Research & Ideas
Open Innovation Contestants Build AI-Based Cancer Tool
significant published and implemented work in AI/algorithmic work already exists, we wanted to direct our interests to a therapeutic problem. The highly technical, image-related work of radiation oncology planning was highly suitable for... View Details
- 14 Aug 2018
- First Look
First Look at New Research and Ideas, August 14, 2018
decide how to bring Elyas on board, and ensure a robust strategy to maintain its leadership position in the region. Purchase this case: https://hbsp.harvard.edu/product/818022-PDF-ENG Harvard Business School Case 818-059 Spark Therapeutics: Pioneering Gene Therapy... View Details
Keywords: by Sean Silverthorne